CliffBio
biologic

Betaseron

interferon beta-1b

Loss of exclusivityJuly 2005projected — 12-year biologic exclusivity estimate
CompanyBayer Healthcare →See this company's full patent-cliff portfolio

Drug detail

Brand nameBetaseron
Active ingredientinterferon beta-1b
Strength0.3MG
Dosage formFor Injection
RouteSubcutaneous
ModalityBiologic
FDA approvalJuly 1993
Marketing statusRx

More from Bayer Healthcare

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Betaseron patent cliff — loss of exclusivity July 2005 | CliffBio